John Griffin - Hologic General Counsel
| HOLX Stock | USD 79.50 0.06 0.08% |
Executive
Mr. John M. Griffin is General Counsel of the Company. Mr. Griffin joined us in February 2015 as General Counsel with nearly 30 years of experience across a broad spectrum of legal matters. Mr. Griffin worked at Covidien from 2000 to 2015 where he most recently served as Vice President, Deputy General Counsel. Previously, from 1994 to 2000, Mr. Griffin served as Assistant United States Attorney in Boston, Massachusetts, and prosecuted complex criminal cases. He began his career at Nutter, McClennen Fish in Boston since 2015.
| Age | 63 |
| Tenure | 9 years |
| Address | 250 Campus Drive, Marlborough, MA, United States, 01752 |
| Phone | 508 263 2900 |
| Web | https://www.hologic.com |
John Griffin Latest Insider Activity
Tracking and analyzing the buying and selling activities of John Griffin against Hologic stock is an integral part of due diligence when investing in Hologic. John Griffin insider activity provides valuable insight into whether Hologic is net buyers or sellers over its current business cycle. Note, Hologic insiders must abide by specific rules, including filing SEC forms every time they buy or sell Hologic'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
John Griffin over two months ago Acquisition by John Griffin of 200 shares of Harte Hanks at 5.6 subject to Rule 16b-3 | ||
John Griffin over six months ago Acquisition by John Griffin of 200 shares of Harte Hanks at 5.62 subject to Rule 16b-3 | ||
John Griffin over six months ago Acquisition by John Griffin of 200 shares of Harte Hanks at 5.66 subject to Rule 16b-3 | ||
John Griffin over six months ago Acquisition by John Griffin of 100 shares of Harte Hanks at 5.649 subject to Rule 16b-3 |
Hologic Management Efficiency
The company has return on total asset (ROA) of 0.0645 % which means that it generated a profit of $0.0645 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1385 %, meaning that it created $0.1385 on every $100 dollars invested by stockholders. Hologic's management efficiency ratios could be used to measure how well Hologic manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to 0.09 in 2024. Return On Capital Employed is likely to drop to 0.08 in 2024. At this time, Hologic's Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 4 B in 2024, whereas Non Current Assets Total are likely to drop slightly above 3.1 B in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Brian Lloyd | Merit Medical Systems | 63 | |
| Shiela Vinczeller | AptarGroup | 60 | |
| Claudia Ortiz | Envista Holdings Corp | N/A | |
| Terry MD | Alcon AG | N/A | |
| Suraj Satpathy | Envista Holdings Corp | N/A | |
| Michael Fliss | ResMed Inc | N/A | |
| Daniel Cravens | Alcon AG | N/A | |
| Rudy Poussot | West Pharmaceutical Services | N/A | |
| Jim Ellis | ResMed Inc | N/A | |
| Filippo Impieri | Envista Holdings Corp | N/A | |
| Ricardo Alvarez | Merit Medical Systems | N/A | |
| Paul Sumilas | Envista Holdings Corp | N/A | |
| Marry Skafidas | AptarGroup | N/A | |
| Mark Butler | Merit Medical Systems | N/A | |
| Marna BronfenMoore | AngioDynamics | 57 | |
| Stephen Keller | Envista Holdings Corp | 50 | |
| Daniel Ackerman | AptarGroup | 51 | |
| David Pendarvis | ResMed Inc | 65 | |
| Shana Neal | Becton Dickinson and | 58 | |
| Mary Skafidas | AptarGroup | N/A | |
| Saleem Cheeks | AngioDynamics | N/A | |
Management Performance
| Return On Equity | 0.14 | ||||
| Return On Asset | 0.0645 |
Hologic Leadership Team
Elected by the shareholders, the Hologic's board of directors comprises two types of representatives: Hologic inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hologic. The board's role is to monitor Hologic's management team and ensure that shareholders' interests are well served. Hologic's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hologic's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Paul Malenchini, Chief Officer | ||
| Peter Dunne, Senior Resources | ||
| Benjamin Cohn, Principal Chief Accounting Officer | ||
| Erik Anderson, Division Solutions | ||
| Mark Irving, VP Secretary | ||
| Stephen MacMillan, Chairman, CEO and Pres | ||
| Kevin Thornal, Group Solutions | ||
| Karleen CPA, Chief Officer | ||
| Scott Christensen, Quality Chain | ||
| John JD, General Counsel | ||
| Elisabeth Hellmann, Sr Communications | ||
| John Griffin, General Counsel | ||
| Jennifer Schneiders, President Solutions | ||
| Mike Kelly, Chief Affairs | ||
| Essex Mitchell, Chief Officer | ||
| Jan Verstreken, Regional President - Europe,Middle EastandAfrica(EMEA) and Canada | ||
| Ryan Simon, Vice Relations | ||
| Karleen Oberton, CFO, Chief Accounting Officer | ||
| Monica Berthelot, VP Staff | ||
| Diana SPHR, Senior Resources | ||
| Brandon Schnittker, Division Solutions |
Hologic Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Hologic a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.14 | ||||
| Return On Asset | 0.0645 | ||||
| Profit Margin | 0.18 % | ||||
| Operating Margin | 0.24 % | ||||
| Current Valuation | 18.37 B | ||||
| Shares Outstanding | 226.94 M | ||||
| Shares Owned By Insiders | 0.80 % | ||||
| Shares Owned By Institutions | 99.20 % | ||||
| Number Of Shares Shorted | 4.59 M | ||||
| Price To Earning | 10.21 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Hologic Stock Analysis
When running Hologic's price analysis, check to measure Hologic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hologic is operating at the current time. Most of Hologic's value examination focuses on studying past and present price action to predict the probability of Hologic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hologic's price. Additionally, you may evaluate how the addition of Hologic to your portfolios can decrease your overall portfolio volatility.